BioNexus Gene Lab Corp. (NASDAQ:BGLC – Get Free Report) was the target of a significant growth in short interest in October. As of October 31st, there was short interest totalling 140,400 shares, a growth of 38.2% from the October 15th total of 101,600 shares. Currently, 1.2% of the shares of the stock are short sold. Based on an average daily volume of 376,900 shares, the short-interest ratio is presently 0.4 days.
BioNexus Gene Lab Stock Down 6.3 %
BioNexus Gene Lab stock traded down $0.02 during midday trading on Friday, reaching $0.30. The company’s stock had a trading volume of 58,550 shares, compared to its average volume of 605,466. BioNexus Gene Lab has a fifty-two week low of $0.28 and a fifty-two week high of $3.39. The business has a 50-day simple moving average of $0.39 and a 200-day simple moving average of $0.46.
BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The company reported $0.01 earnings per share (EPS) for the quarter. BioNexus Gene Lab had a negative return on equity of 23.07% and a negative net margin of 24.01%. The firm had revenue of $1.98 million for the quarter.
Institutional Investors Weigh In On BioNexus Gene Lab
BioNexus Gene Lab Company Profile
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.
Featured Stories
- Five stocks we like better than BioNexus Gene Lab
- Earnings Per Share Calculator: How to Calculate EPS
- How Whitestone REIT is Transforming Sunbelt Retail Growth
- What is Put Option Volume?
- Top-Performing Non-Leveraged ETFs This Year
- Want to Profit on the Downtrend? Downtrends, Explained.
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.